Illumina (NASDAQ:ILMN) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen lowered shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research note released on Saturday morning.

Several other equities research analysts have also commented on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. TD Cowen boosted their price target on Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a research note on Friday, October 31st. Evercore ISI increased their price target on Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Robert W. Baird set a $109.00 price objective on shares of Illumina in a research report on Friday, October 31st. Finally, Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 2nd. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $118.31.

Illumina Trading Up 2.4%

ILMN opened at $134.35 on Friday. Illumina has a twelve month low of $68.70 and a twelve month high of $153.06. The company has a fifty day moving average of $125.81 and a 200-day moving average of $107.86. The stock has a market cap of $20.53 billion, a PE ratio of 30.12, a price-to-earnings-growth ratio of 2.24 and a beta of 1.41. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. Illumina’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts predict that Illumina will post 4.51 EPS for the current year.

Insider Buying and Selling

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their position. The SEC filing for this purchase provides additional information. 2.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently bought and sold shares of ILMN. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC purchased a new stake in Illumina in the 3rd quarter valued at about $29,000. Quarry LP purchased a new stake in Illumina in the 3rd quarter valued at about $32,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Illumina during the 3rd quarter worth approximately $33,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.